The FTSE 100 Index Closes 1.43% Higher

2026-03-30 16:07 By TRADING ECONOMICS 1 min. read

The FTSE 100 Index gained 143 points or 1.43 percent on Monday to close at 10110 points.

Gains were led by Burberry (4.09%), Land Securities (3.90%) and London Stock Exchange (3.80%).



News Stream
The FTSE 100 Index Closes 1.43% Higher
The FTSE 100 Index gained 143 points or 1.43 percent on Monday to close at 10110 points. Gains were led by Burberry (4.09%), Land Securities (3.90%) and London Stock Exchange (3.80%).
2026-03-30
FTSE 100 Starts the Week Higher
The FTSE 100 climbed over 1% on Monday, rebounding after a recent sell-off driven by concerns over the impact of the war in Iran. UK stocks followed gains in Europe and the US, boosted by Federal Reserve Chair Jerome Powell’s comments that longer-term inflation expectations remain under control. Oil giants Shell and BP rose 2% and 2.5% respectively, as oil markets approach their largest monthly gain. Major banks, including HSBC Holdings, Lloyds Banking, Barclays, and Natwest, advanced 0.3%-1.1%. Mining stocks also surged, with Rio Tinto up 3% and Glencore 2.5%. Conversely, the travel and leisure sector remained under pressure, with International Airlines Group down 1.9% and Easyjet Plc falling 1.1%. Recent data showed mortgage approvals increased in February, and consumer borrowing is rising.
2026-03-30
FTSE 100 Flat as Energy, Mining Gains Offset Banks
The FTSE 100 traded near flat on Monday in a muted start for European markets, though it outperformed slightly thanks to gains in mining and energy stocks. Investor sentiment remained cautious amid concerns the Iran conflict could escalate. Higher oil prices supported BP and Shell, both up around 0.9%, while miners also advanced with Rio Tinto rising more than 3% and Glencore gaining nearly 1%. On the downside, banking stocks were weaker, with HSBC down 1%, Lloyds off 0.5%, Barclays falling 0.7% and NatWest slipping 0.6%. Travel and leisure names lagged as EasyJet and InterContinental Hotels dropped about 1.5% each. In other news, GSK said its hepatitis B treatment bepirovirsen has been accepted for regulatory review in China, with shares little changed.
2026-03-30